In 2021, Bioventus will gain preferred access through the CVS Caremark Formulary, to DUROLANE®, GELSYN-3® and SUPARTZ FX® for the treatment of knee osteoarthritis (OA) pain. CVS Caremark manages drug benefits for more than 40 million lives, including prescription drug benefits of 6 million Aetna members.
DUROLANE single-injection, GELSYN-3 three-injection and SUPARTZ FX five-injection hyaluronic acid-based joint-fluid treatment will be among the four preferred standard formulary options of knee OA treatments for CVS Caremark members.
“CVS Caremark members now have access to the broadest HA portfolio available to patients and physicians in the U.S.,” said John Nosenzo, Chief Commercial Officer, Bioventus. “DUROLANE, GELSYN-3 and SUPARTZ FX, all from Bioventus, provide long lasting OA knee pain relief allowing patients to resume more active lives.”